XJZY(SZ:002332) Xin Lang Cai Jing·2025-09-18 01:31Core Insights - Xianju Pharmaceutical experienced a decline of 1.07% in stock price on September 17, with a trading volume of 172 million yuan [1] - The company reported a financing net buy of -6.08 million yuan on the same day, indicating a higher level of financing repayment compared to new purchases [1][2] - As of September 8, the number of shareholders increased by 8.70% to 50,000, while the average circulating shares per person decreased by 8.00% to 19,691 shares [2] Financing and Margin Trading - On September 17, Xianju Pharmaceutical had a financing buy amount of 18.39 million yuan, with a total financing balance of 639 million yuan, representing 6.36% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of financing activity [1] - The company had no shares repaid in margin trading on September 17, with 300 shares sold short, amounting to 3,048 yuan [1] Financial Performance - For the first half of 2025, Xianju Pharmaceutical reported a revenue of 1.869 billion yuan, a year-on-year decrease of 12.56%, and a net profit attributable to shareholders of 308 million yuan, down 9.26% year-on-year [2] - Cumulatively, the company has distributed 1.932 billion yuan in dividends since its A-share listing, with 890 million yuan distributed in the last three years [3] Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included the Southern CSI 1000 ETF, which increased its holdings by 1.4094 million shares to 7.3351 million shares [3] - Hong Kong Central Clearing Limited and Xingquan He Feng Mixed Fund exited the list of top ten circulating shareholders [3]